Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/29/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. David S. Baskin

Wrong Dr. David S. Baskin?

Professor, Neurosurgery and Direc...

Houston Methodist Hospital
Phone: (713) ***-****  
Email: d***@***.org
Houston Methodist
6565 Fannin Street
Houston , Texas 77030
United States

Company Description: Houston Methodist is a nonprofit health care organization based in Houston, Texas. It has extended the world-renowned clinical and service excellence of its...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • M.D.
  • Swarthmore College
  • Mt. Sinai School of Medicine
  • departments of Neurosurgery and Anesthesiology
    Baylor College of Medicine
125 Total References
Web References
"Glioblastoma is the most malignant brain ...
www.iran-daily.com, 1 June 2015 [cached]
"Glioblastoma is the most malignant brain tumor you can have," said study co-author Dr. David Baskin, professor of neurosurgery with both Houston Methodist Hospital and the Weill-Cornell College of Medicine in New York City. "It's almost always a death sentence, with median survival of about nine to 15 months, and the quality of life during the last five months is often quite poor.
"Surgery, along with chemotherapy and radiation, is the only current treatment option," he added. "This cancer is like an octopus -- it reaches into all parts of the brain [and] you can only ever get some of it out."
"However, this particular gene therapy is better than anything else we have," said Baskin, who also directs the Peak Brain Tumor Center at the Houston hospital. "By inserting a virus into the tumor, then attacking that virus with medication while also firing up the patient's own immune system, you can get a real one-two punch treatment effect, and prolonged survival."
He stressed that the treatment may not be a cure. "The [survival] numbers still stink," Baskin said.
"Glioblastoma is the most malignant brain ...
palmswestsurgicenter.com, 31 May 2015 [cached]
"Glioblastoma is the most malignant brain tumor you can have," said study co-author Dr. David Baskin, professor of neurosurgery with both Houston Methodist Hospital and the Weill-Cornell College of Medicine in New York City. "It's almost always a death sentence, with median survival of about nine to 15 months, and the quality of life during the last five months is often quite poor. "Surgery, along with chemotherapy and radiation, is the only current treatment option," he added. "This cancer is like an octopus -- it reaches into all parts of the brain [and] you can only ever get some of it out." However, "this particular gene therapy is better than anything else we have," said Baskin, who also directs the Peak Brain Tumor Center at the Houston hospital. "By inserting a virus into the tumor, then attacking that virus with medication while also firing up the patient's own immune system, you can get a real one-two punch treatment effect, and prolonged survival." He stressed that the treatment may not be a cure. "The [survival] numbers still stink," Baskin said. "But they're significantly better, which makes this a big advance." Baskin and his team are slated to present their findings Sunday in Chicago at the annual meeting of the American Society of Clinical Oncology.
...
The result, said Baskin, is that "suddenly the immune system starts killing anything that might have these proteins. So you put the Trojan horse virus in. Then, after you kill the virus the tumor cells explode, causing the immune system to hyper-activate without raising toxicity [to the patient]." "It's interesting and exciting, because the improvement [in survival] is significant," Baskin said. How significant? Specifically, one-year survival rose from 57 percent to 67 percent; two-year survival rose from 22 percent to 35 percent; and the number of patients who lived at least three years rose from 8 percent to 19 percent, the study team found. Overall, average survival improved by about eight months, researchers say. "We're not saying we have a cure, of course," noted Baskin.
...
SOURCES: David Baskin, M.D., professor, neurosurgery, and director, Kenneth R. Peak Brain Tumor Center, Houston Methodist Hospital, Houston, Texas, and professor, neurosurgery, Weill-Cornell College of Medicine, New York City; Balveen Kaur, Ph.D., professor, neurological surgery, and associate director, Medical Center at the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio; May 31, 2015, presentation, annual meeting, American Society of Clinical Oncology, Chicago, Ill.
"This is a group of patients ...
www.orovillehospital.com, 11 Mar 2015 [cached]
"This is a group of patients that desperately need a new approach, and this is a clever and exciting approach," said Dr. David Baskin, director of the Peak Brain and Pituitary Tumor Center at Houston Methodist Hospital in Texas, who wasn't involved in the new study but has participated extensively in other brain tumor research.
"All of us in the field are eager to move away from standard chemotherapy ... and trying to attack some basic thing that cancer cells just can't do without, an Achilles' heel in the cancer," added Baskin, also vice chairman of the hospital's department of neurosurgery.
"So the idea of using the immune system to treat cancer conceptually makes sense," he said.
...
SOURCES: Kristen Batich, M.D.-Ph.D. student, Duke University, Durham, N.C.; David Baskin, M.D., vice chairman, department of neurosurgery, and director, Peak Brain & Pituitary Tumor Center, Houston Methodist Hospital; March 11, 2015, Nature, online
David Baskin, ...
onkuretherapeutics.com, 9 July 2015 [cached]
David Baskin, M.D.
Scientific Advisor Biography
Dr. Baskin graduated from Swarthmore College with high honors in the Division of Natural Sciences and Engineering. He attended the Mt. Sinai School of Medicine in New York, where he graduated first in his class, and received the James Felt Prize for the highest overall performance during the four years of medical school training.
He then received his surgical and neurosurgical training at the University of California in San Francisco. Dr. Baskin began his research career while still a resident at the University of California San Francisco (UCSF). In 1982, he spent a year as a Research Associate at the University of Capetown Medical School and Groote Schuur Hospital in Capetown, South Africa. The following year, Dr. Baskin returned to UCSF and served as a Research Associate in the Hormone Research Laboratory. Based on novel research demonstrating ways to restore brain function, he won the American Academy of Neurosurgery Award for the best research performed by a neurosurgery resident.
After completing his residency, Dr. Baskin was appointed as Assistant Professor of Neurological Surgery and Assistant Professor of the Center for Biotechnology at Baylor College of Medicine, with a joint appointment as Chief of Neurological Surgery at the VA Hospital. In 1994 he was promoted to Professor at Baylor College of Medicine in the departments of Neurosurgery and Anesthesiology, positions he held until 2005 when his academic career transitioned to Houston Methodist.
...
David Baskin, M.D. Scientific Advisor Biography
Dr. Baskin graduated from Swarthmore College with high honors in the Division of Natural Sciences and Engineering. He attended the Mt. Sinai School of Medicine in New York, where he graduated first in his class, and received the James Felt Prize for the highest overall performance during the four years of medical school training.
He then received his surgical and neurosurgical training at the University of California in San Francisco. Dr. Baskin began his research career while still a resident at the University of California San Francisco (UCSF). In 1982, he spent a year as a Research Associate at the University of Capetown Medical School and Groote Schuur Hospital in Capetown, South Africa. The following year, Dr. Baskin returned to UCSF and served as a Research Associate in the Hormone Research Laboratory. Based on novel research demonstrating ways to restore brain function, he won the American Academy of Neurosurgery Award for the best research performed by a neurosurgery resident.
After completing his residency, Dr. Baskin was appointed as Assistant Professor of Neurological Surgery and Assistant Professor of the Center for Biotechnology at Baylor College of Medicine, with a joint appointment as Chief of Neurological Surgery at the VA Hospital. In 1994 he was promoted to Professor at Baylor College of Medicine in the departments of Neurosurgery and Anesthesiology, positions he held until 2005 when his academic career transitioned to Houston Methodist.
Today's News
www.prnewswire.com, 28 Sept 2001 [cached]
A landmark number of 44 proposals were submitted to the Cure Autism Now special review panel headed by David Baskin , M.D. , a neurosurgeon at Baylor College of Medicine.Dr. Baskin led the review process with eight other scientists with experience related to the toxicology of heavy metals.
Other People with the name "Baskin":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.